Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The tablets are indicated for the treatment of pulmonary arterial hypertension
The company plans to expand their capacity to meet the needs of pharma and biotech industries
It plans to add over 1000 employees over the next six months
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
